Understand the signs of premature ovarian failure and POI. Learn how to manage symptoms and protect your long-term health.

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating ...

The FDA has granted Fast Track Designation to CTIM-76, a claudin-6 (CLDN6) x CD3 T cell engaging bispecific antibody, for the ...

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments. The U.S. Food and Drug Administration (FDA) ...

Corcept Therapeutics wins early FDA approval for Lifyorli in platinum-resistant ovarian cancer, boosting growth outlook.

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

Experts underscored that while maternal age remains the most decisive factor, rising cases of early ovarian decline among ...

Shares of Context Therapeutics rose after the Food and Drug Administration moved to expedite its review of the biopharmaceutical company's treatment for ovarian cancer. The stock climbed 8.7% to $2.88 ...

OverT builds scalable, cost-effective immune therapies for solid tumors using its data-driven discovery platformsNEW YORK--(BUSINESS WIRE)--#Biotech--OverT Bio, a biotechnology company developing next ...

The Society of Gynecologic Oncology (SGO) will convene leading experts in gynecologic oncology at its 2026 Annual Meeting on Women's Cancer, to be held April 10--13, 2026, in San Juan, Puerto Rico.

Dr Bradley Corr discusses what he’s most excited to hear at the SGO Annual Meeting, including new data on antibody-drug ...